Teva Pharmaceuticals Transitions to Direct NYSE Trading, CEO Explains Strategic Shift

Source Summary

Teva Pharmaceuticals President & CEO Richard Francis discussed the company's decision to transition its shares from American Depositary Receipts (ADRs) to direct trading on the New York Stock Exchange. The CEO explained the rationale for the timing of this change and outlined how the transition will affect investors.

Why it matters

The shift from ADRs to direct NYSE trading simplifies the trading mechanism for investors and may improve liquidity and accessibility for Teva shares.

Read the Source

Bloomberg ↗

NYSE:TEVALive chart

Trading trends

The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.

Recent SEC-reported share and derivative transactions in TEVA PHARMACEUTICAL INDUSTRIES LTD.

Insider activity sentiment

Bearish

BearishNeutralBullish

0 discretionary purchases · 4 discretionary sales

Confidence: High

Informative buyNon-informative buyInformative sellNon-informative sell

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
Chief Accounting OfficerWeiss Amir	Informative sell	Ordinary SharesOpen-market or private transaction (S)	6,945	$37.6133	$261,224	Aug 21, 2026
Chief Accounting OfficerWeiss Amir	Informative sell	Open-market or private transaction

Show 121 more transactions

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
DirectorZaks Tal Zvi	Informative sell	Ordinary SharesOpen-market or private transaction (S)	17	$34.8655	$593	Aug 5, 2026
See "Remarks"Jover Placid	Non-informative sell

As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.

Short interest

Open short positions reported twice monthly; this is not daily short-sale volume.

Comments

No published comments yet.

Settlement date	Short interest	Avg. daily volume	Change vs. previous report	Days to cover
Aug 31, 2026	37,614,253	4,877,029	+5.45%	7.71
Aug 14, 2026	35,670,864	5,379,181	+3.93%	6.63
Jul 31, 2026	34,320,980	5,976,563	+4.83%	5.74
Jul 15, 2026	32,741,011	5,031,824	+2.22%	6.51
Jun 30, 2026	32,029,657	6,283,326	-3.95%	5.10
Jun 15, 2026	33,346,891	6,149,216	-1.54%	5.42
May 29, 2026	33,869,008	5,646,510	+27.08%	6.00
May 15, 2026	26,651,458	6,682,365	-14.42%	3.99

Source Summary

Why it matters

Read the Source

NYSE:TEVA — Live chart

Insider activity sentiment

Comments

Related stories

Teva Prices $4.9 Billion Senior Notes Offering to Refinance Existing Debt

Turkish Antitrust Authorities Investigate Teva for Alleged Patent System Manipulation and Rival Drug Disparagement

Energy Transfer to Move Primary Listing to Texas Stock Exchange From NYSE

Comments

Insider activity sentiment

NYSE:TEVALive chart